Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 913

Gears of Lenacapavir for PrEP Rollout 

The Gears of Lenacapavir for PrEP Rollout outlines a transformative opportunity in the global fight against HIV, coming at a pivotal moment when the scale-up of PrEP has shown remarkable progress but remains insufficient to achieve a transformational impact on HIV incidence and the trajectory of the epidemic.

Prevention Option:

December 2024


The Gears Framework for Lenacapavir for PrEP Rollout

The gears framework for lenacapavir scale-up brings together a coalition of essential stakeholders, each contributing to the successful, sustainable integration of this HIV prevention tool into global health systems.

Prevention Option:

December 2024


No Data No More Scorecard Tool

This scorecard advocacy tool synthesizes the visions put forth in the No Data No More Manifesto to Align HIV Prevention Research with Trans and Gender-Diverse Realities into scorable indicators to help realize trans-inclusivity in research.

November 2024


PrEP Initiations by Country Worldwide

AVAC tracks global PrEP use by conducting quarterly surveys of ongoing oral PrEP demonstration and implementation projects, and collecting data from manufacturers and government agencies. This graphic shows data on PrEP initiations around the globe.

Prevention Option:

November 2024


An Advocate’s Guide to Research in Pregnant and Lactating Populations

A resource that provides background on the need for research in pregnant and lactating populations and how advocates can advance inclusion.

November 2024


Moving a Product to the “Real World”

A visual roadmap illustrating the key stages transitioning a product from clinical trials to large-scale real-world implementation.

Prevention Option:

November 2024


PxPulse: The Votes are In — What’s next for the US’ role in global health and HIV prevention

In the days ahead under a new US Presidential Administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention. And there will be major implications for the global AIDS response.

Prevention Option:

November 2024


Dapivirine Vaginal Ring Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Cabotegravir Regulatory Approval

Regulatory approvals and those pending for cabotegravir as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Dapivirine Vaginal Ring Volume

DVR supply available to low- and middle-income countries as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


showing 1-10 of 913